Damon Daniels, MD
Family Medicine · Columbia, SCNPI 1235104464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 882 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 882 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novartis$1K
- Pfizer$1K
- Novo Nordisk$839
- Amgen$794
- Kowa Pharmaceuticals America, Inc.$735
- plus $9K from 54 others
Across 24 payments — averaging $11,876 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- Exact Sciences$120K
- Chiesi USA, Inc.$17K
- Modernatx, Inc.$17K
- Vivus LLC$5K
- Sanofi Pasteur Inc.$4K
What the payments were for
- Consulting fees$1,0567%
- Food & beverage$14,05592%
- Education$1991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAKVEO$1,056
- HMG-CoA reductase inhibitor.$534
How this compares
$15,310 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 131 | $131,205 |
| OzempicSemaglutide | 100 | $122,039 |
| EliquisApixaban | 90 | $85,880 |
| JanuviaSitagliptin Phosphate | 105 | $84,621 |
| JardianceEmpagliflozin | 91 | $75,230 |
| MounjaroTirzepatide | 58 | $66,842 |
| TrulicityDulaglutide | 33 | $56,431 |
| MyrbetriqMirabegron | 72 | $53,474 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $45,095 |
| LinzessLinaclotide | 44 | $33,907 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $22,028 |
| TradjentaLinagliptin | 15 | $17,183 |
| UbrelvyUbrogepant | 11 | $17,036 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $15,766 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $14,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,807 | $146,971148 claims |
| Novo NordiskOzempic, Rybelsus | $839 | $132,318111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $687 | $123,27291 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $575 | $104,041121 claims |
| MerckJanuvia, Janumet Xr | $138 | $99,364124 claims |
| PfizerEliquis | $1,120 | $85,88090 claims |
| Astellas Pharma US IncMyrbetriq | $276 | $53,47472 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $345 | $52,64161 claims |
| AbbVieLinzess, Ubrelvy | $656 | $50,94355 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $596 | $22,02825 claims |
| Johnson & JohnsonXarelto, Invokana | $117 | $17,80425 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $735 | $14,04725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Columbia
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Terry NagelColumbia$112K
- John MatteiColumbia$15K
- Conigliaro JonesColumbia$14K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Jeffrey BroderNorth Augusta$140K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.